---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-22-000043"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:32:53.990412+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences FY2021 revenue $94.1M (+50% YoY); guides FY2022 $115-120M

## Summary
- Full-year 2021 revenue $94.1M, up 50% vs $62.6M in 2020; net loss $(31.3)M vs $(10.3)M.
- Total GEP test volume 28,118 (+55% YoY); DecisionDx-Melanoma 20,328 (+25%).
- Q4 revenue $25.0M (+45% YoY); delivered 8,242 test reports (+60%).
- Cash and equivalents $330M at Dec. 31, 2021; adjusted EBITDA $(14.9)M for 2021.
- FY2022 revenue expected $115-120M; includes TissueCypher Barrett's esophagus test.

## SEC filing metadata
- accession: 0001447362-22-000043
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000043/0001447362-22-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000043/cstl-20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-22-000043
- JSON: https://secwatch.observer/filing/0001447362-22-000043.json
- Plain text: https://secwatch.observer/filing/0001447362-22-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.